Evaluation of Cancer Ratio Plus in Differentiating Malignant Pleural Effusions from Non-malignant Pleural Effusions
Apollo Medicine · 20.05.2026
DOI: 10.1177/09760016261446812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apollo Medicine, online erschienen am 20.05.2026. Verfasst von Tarakaturi Sharon Swarna Sheela und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Malignant pleural effusion (MPE) is the second most common cause of exudative pleural effusion with a reduced life expectancy. Hence, diagnosing MPE is important for early intervention and management to improve survival. Histopathological examination of pleural fluid (PF) has an accuracy of 40% to 87% for diagnosing MPE [ 8 ]. When the malignancy is not diagnosed, a closed or thoracoscopic pleural biopsy is performed to establish the diagnosis, but a closed pleural biopsy adds only 8% to the overall yield. Hence, pleural effusion remains undiagnosed in situations when the patient refuses the thoracoscopic biopsy or when the test is unavailable. Cancer ratio (CR), that is, the ratio of serum Lactate Dehydrogenase (LDH) to pleural fluid Adenosine Deaminase (ADA) and Cancer Ratio plus, that is, the ratio of Cancer Ratio to pleural fluid lymphocyte count are markers which may be a ‘forewarning’ to patients who are not diagnosed by cytology but later confirmed to have MPE. The aim in this study is to test the diagnostic potential of CR plus (CR/PF lymphocyte count) in identifying MPE from other effusions. (CR = serum LDH/PF ADA)
Methods
Prospective observational study done from August 2022 to June 2024.
Results
Among the total of 110 patients included in the study, the mean of CR plus is 50.63 ± 30.772 among MPE and 12.45 ± 18.08 among non-MPE. At a cut-off of 20.5, the sensitivity and specificity of CR plus are 95.1% and 92.7%, respectively.
Conclusion
Triage of patients presenting with exudative lymphocytic but diagnostically inconclusive pleural effusion can be facilitated by using biochemical markers such as the CR and CR plus, which are simple, affordable and widely available.
Zitieren
APA
Sheela, T. S. S., Kumar, R. S., Maddala, S. A., Sreerama, P., & Kurian, N. (2026). Evaluation of Cancer Ratio Plus in Differentiating Malignant Pleural Effusions from Non-malignant Pleural Effusions. Apollo Medicine. https://doi.org/10.1177/09760016261446812
Vancouver
Sheela TSS, Kumar RS, Maddala SA, Sreerama P, Kurian N. Evaluation of Cancer Ratio Plus in Differentiating Malignant Pleural Effusions from Non-malignant Pleural Effusions. Apollo Medicine. 2026. doi:10.1177/09760016261446812
BibTeX
@article{Sheela2026,
author = {Sheela, Tarakaturi Sharon Swarna and Kumar, Raghumanda Sunil and Maddala, Shanti Annapurna and Sreerama, Praveena and Kurian, Nithin},
title = {Evaluation of Cancer Ratio Plus in Differentiating Malignant Pleural Effusions from Non-malignant Pleural Effusions},
journal = {Apollo Medicine},
year = {2026},
doi = {10.1177/09760016261446812}
}
EUVIMED